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Thymopentin (TP5) triggers an immune response by contacting with T cells; however the molecular basis of how TP5 achieves
this process remains incompletely understood. According to the main idea of immunomodulation, we suppose that it would be
necessary for TP5 to form complex with human class II major histocompatibility complex DR molecules (HLA-DR) before TP5
interacts with T cells. The uptake of TP5 by EBV-transformed B cells expressing HLA-DR molecules and the histogram of
fluorescence intensities were observed by using fluorescent- labeled TP5, testifying the direct binding of TP5 to HLA-DR. The
binding specificity was confirmed by the inhibition with unlabeled TP5, suggesting the recognition of TP5 by HLA-DR. To
confirm the interaction between TP5 and HLA-DR, the complex formation was predicted by using various modeling strategies
including six groups of trials with different parameters, alanine substitutions of TP5, and the mutants of HLA-DR. The results
demonstrated that TP5 and its alanine substitutions assumed distinct conformations when they bound to HLA-DR. The
observation further showed that there was flexibility in how the peptide bound within the binding cleft. Also, the molecular
analysis supplemented a newly important discovery to the effect of Val anchor on TP5 binding HLA-DR, and revealed the
important effects of Glu11 and Asn62 on the recognition of TP5. These results demonstrated the capability of TP5 to associate
with HLA-DR in living antigen presenting cells (APC), thereby providing a new and promising strategy to understand the
immunomodulation mechanism induced by TP5 and to design potential immunoregulatory polypeptides.
Citation: Liu Z, Zheng X, Wang J, Wang E (2007) Molecular Analysis of Thymopentin Binding to HLA-DR Molecules. PLoS ONE 2(12): e1348.
doi:10.1371/journal.pone.0001348
INTRODUCTION
Thymopentin (TP5) is a synthetic pentapeptide, corresponding to
position 32,36 of thymopoietin [1]. TP5 exhibits a similarly
biological activity as thymopoietin responsible for phenotypic
differentiation of T cells and the regulation of immune systems [2].
It had been recognized as an immunomodulator for the treatment of
primary immunodeficiencies, such as AIDS [3], rheumatoid arthris
(RA) [4] and autoimmune diseases [5] etc. Although the biological
role of TP5 has been well elucidated by making contact with T cells,
relatively few efforts have been made to clarify the refined
mechanism of its action. For the standard paradigm of T-cell
mediated immune response, T cell receptors (TCRs) only recognize
foreign antigens stably bound to MHC molecules [6–10]. Recently,
it had been shown that human CD 4 T cells expressed functional
class II major histocompatibility complex molecules (MHC II) [11].
Thus,we deducethat itwouldbenecessaryforTP5 toformcomplex
with MHC II molecules before it interacts with T cells.
MHC II molecules are proteins anchored in the cell membrane
of APC, where they present antigenic peptides to CD4 positive T
helper cells [12,13]. Recent advances had provided insights into
how MHC interacted with peptides [14–22] and a rationale to
predict optimal epitopes of MHC-binding [23,24]. It is important
to note that most of the well-known ligands were derived from
naturally MHC-bound peptides and T-restricted epitopes. For
synthetic peptides known as clinical drugs, there are few reports on
their direct binding MHC in living APC.
In the present study, we have established combined experimental
and computational strategies to verify the hypothesis of the complex
formation of MHC II/TP5. Taking advantage of confocal-laser
scanning microscopy (CLSM) and flow cytometry (FCM) tech-
niques, we examined the binding of fluorescent-labeled TP5 to
HLA-DR inlivingAPC insituwith anapparentdissociation constant
(Kd)o f7 . 2 610
26 M. Furthermore, the binding specificity was tested
by competitive binding assay with unlabeled TP5. The molecular
modeling of the interaction between ligands and receptors
demonstrated that TP5 and its alanine substitutions adopted distinct
conformations when they bound to HLA-DR. The observation
further showed that there was flexibility in peptide binding with
MHC II binding cleft. More importantly, the molecular analysis
supplemented a newly important discovery to the effect of Val
anchor on TP5 binding HLA-DR. Also, the molecular analysis
revealed the key effects of Glu11 and Asn62 on the recognition of
TP5 based on the mutants of HLA-DR. The study provides a better
understanding to the mechanism of interaction between TP5 and
TCRs and a rational strategy to design TP5 analogs.
RESULTS
Uptake of FITC-labeled TP5 by EBV-transformed B
cells
To validate the ability of FITC-labeled TP5 to load on EBV-
transformed B cells expressing HLA-DR, a qualitative CLSM
assay was used to examine the fluorescent signal of EBV-
Academic Editor: Martin Egli, Vanderbilt University, United States of America
Received May 30, 2007; Accepted November 17, 2007; Published December 26,
2007
Copyright:  2007 Liu et al. This is an open-access article distributed under the
terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author
and source are credited.
Funding: This work was supported by the National Natural Science Foundation of
China with the Grant No. 20575063, 90713022, 20735003 and Chinese Academy
of Sciences KJCX2.YW.H09. J. W thanks National Science Foundation Career Award
and American Chemical Society Petroleum Research Fund for financial supports.
The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: jin.wang.1@
stonybrook.edu (JW); ekwang@ciac.jl.cn (EW)
PLoS ONE | www.plosone.org 1 December 2007 | Issue 12 | e1348transformed B cells. The surface fluorescence was hardly observed
from the cells in the absence of FITC-labeled TP5 at the excitation
of 488 nm (Fig. 1A). In sharp contrast to this observation, the
strong surface fluorescence was found for the cells in the presence
of FITC-labeled TP5 at the same conditions (Fig. 1B). These
findings indicated that the green fluorescence could attribute to the
loading of FITC-labeled TP5 onto the EBV-transformed B cells.
Direct binding of FITC-labeled TP5 to EBV-
transformed B cells
Although the uptake of FITC-labeled TP5 in EBV-transformed B
cells was confirmed, the correlation between the binding affinity of
FITC-labeled TP5 to EBV-transformed B cells and the fluorescence
intensity in cells was not showed clearly. Therefore, a quantitative
flow cytometric assay wasused to get a betterinsight into thebinding
affinity of TP5 to HLA-DR on the surface of EBV-transformed B
cells. As shown in Fig. 2, the binding of FITC-labeled TP5 to EBV-
transformed B cells was in a dose-dependent manner, and the
equilibrium could be achieved at 100 mM of antigen. An apparent
Kd of 7.2610
26 M was obtained from the double- reciprocal plot of
the equilibrium binding data (Fig. 3), implying that TP5 markedly
bound to HLA-DR. Simultaneously, a correlation with R
2=0.9903
and a slope of 0.01311 were obtained. We then compared the
specific binding of FITC-labeled TP5 to HLA-DR. In Fig. 4, the
histogram of fluorescence intensities indicated that almost the same
extent cells (94% vs. 95%, respectively) were stained by FITC-
labeled TP5 and mAb-DR FITC above the background, with an
approximately 3 orders of magnitude increase in mean fluorescence
intensity (MFI). The fluorescent signal showed the strongly direct
binding of FITC-labeled TP5 to HLA-DR expressed on the surface
of EBV-transformed B cells.
Competitive binding assay
Next, we examined whether the blocking of HLA-DR on the
surface of APC would lead to the inhibition of mAb-DR binding.
A distinct change of fluorescence intensity was observed when
unlabeled TP5 was preincubated with EBV-transformed B cells,
followed by incubation with mAb-DR FITC. With increasing the
Figure 1. Uptake of FITC-labeled TP5 by EBV-transformed B cells. Confocal images were taken in living cells in the absence (A) and presence (B) of
FITC-labeled TP5. The scale bar corresponds to 20 mm.
doi:10.1371/journal.pone.0001348.g001
Figure 2. Direct binding of FITC-labeled TP5 to EBV-transformed B
cells. The mean binding data for various concentrations of FITC-labeled
TP5 were shown as mean fluorescence intensities of triplicates6SD.
doi:10.1371/journal.pone.0001348.g002
Figure 3. Double-reciprocal plot of the equilibrium binding data.
Representative binding data for various concentrations of antigen were
expressed as mean fluorescence intensities of triplicates6SD.
doi:10.1371/journal.pone.0001348.g003
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level of MFI (Fig. 5A). The change of MFI was dependent on the
concentrations of TP5 used in the competitive binding assay
(Fig. 5B). The reduction of MFI indicated that TP5 bound to
HLA-DR and inhibited the binding of mAb-DR to HLA-DR. The
competitive binding assay implied that the fluorescence intensity
was correlated with the amount of HLA-DR on the surface of
APC. The observation further indicated that TP5 restrained the
binding of mAb-DR to HLA-DR molecules.
Molecular modeling of the interaction between TP5
and HLA-DR
The first five dockings were terminated based on the endpoint of the
number of energy evaluations listed in Table 1. As a result, the
maximum number of generations was less than 27000 in these runs.
Whereas, the sixth docking was terminated based on the endpoint of
the maximum number of generations (27000), and the number of
energy evaluations was 100 million. From the current data, it could
be clearly seen that the number of energy evaluations had an
influence on the docking energy generated from six trials. We found
that the last trial converged to a stably native binding mode. We also
found the binding modes with lowest energy generated from other 5
trials shared some common features with the native binding mode in
the last trial. This illustrated that the common features shared by
different trials might be crucial for the binding of TP5 to HLA-DR.
This means that few stable binding conformations could be found
below 100 million energy evaluation.
More importantly, we found that Gln9 and Lys250, locating in
the brim of the binding site, were ineffective to direct peptides to
bind into the binding cleft. On the contrary, the interactions
between peptide and Glu11 and Asn62 played a key role in
Figure 4. The binding of FITC-labeled TP5 onto the surface of EBV-
transformed B cells. EBV-transformed B cells were incubated with PBS
alone (trace a), FITC-labeled TP5 (trace b) and mAb-DR FITC (trace c),
and then subjected to flow cytometry. The vertical line was the
boundary between bound and unbound cells.
doi:10.1371/journal.pone.0001348.g004
Figure 5. Inhibition of the binding of mAb-DR FITC by unlabeled TP5. Results were shown by the decrease of MFI (A) and the percent inhibition of
MFI (B). The data points shown were the mean values of triplicates6SD.
doi:10.1371/journal.pone.0001348.g005
Table 1. Docking energies of six groups of trials under
different energy evaluations.
......................................................................
Trials Energy evaluations (610
6)
aEdocked/
bEfree (kcal/mol)
15 215.54/26.68
2 7.5 216.95/27.95
31 0 216.48/29.16
42 0 215.18/26.02
55 0 217.21/29.22
61 0 0 217.86/29.25
aEdocked represents the sum of the intermolecular and internal energies of
ligands;
bEfree represents the free energy evaluated by the method provided in the
autodock package.
doi:10.1371/journal.pone.0001348.t001
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PLoS ONE | www.plosone.org 3 December 2007 | Issue 12 | e1348orientation, suggesting that both the residues were obligatory
during the binding of TP5 into the binding cleft.
On the basis of Autodock3.0.5 method, a certain number of
energy evaluations may converge to a correct energy minimum.
That implies more members of the populations will be converged
to the lowest energy conformation [25]. Thus, if the energy
evaluation is further increased, the system will be remained at the
same conformation. According to the rule, the maximum number
of energy evaluations was set to 100 million for the following
calculations. Confirming the complex formation between TP5 and
HLA-DR, we assessed the ability of HLA-DR to functionally
recognize alanine substitutions of TP5 under the same parameters.
The best complexes with the lowest binding energy and the same
direction between peptides and the groove were used as the inputs
for further minimization. In Table 2, the binding energy of TP5
binding to HLA-DR was the least value among six binding
energies. This result means that the most stable complex of HLA-
DR/TP5 was formed (Fig. 6A). Remarkably, the substitution of
Arg at position 1 considerably reduced the binding affinity.
However, as shown in Fig. 6B, the alanine substitution of Arg
stretched into the cleft deeply and bound to the same binding site
with Glu11 and Asn62, which accounted for its obligatory nature
for Arg at position 1 for actual interacting with the receptor. In
Figure 6. The predicted binding of TP5 and its alanine substitutions to HLA-DR. The key residues (E11, N62) are in red; the other contacted
residues are in orange. Peptide variants correspond to A: RKDVY; B: AKDVY; C: RADVY; D: RKAVY; E: RKDAY; F: RKDVA.
doi:10.1371/journal.pone.0001348.g006
Table 2. The effect of alanine substitutions of TP5 on binding
HLA-DR.
......................................................................
Substitutions Binding energy (kcal/mol) Key residues
RKDVY 28.99 E11, N62
AKDVY 26.31 E11, N62
RADVY 27.27
RKAVY 27.18 N62
RKDAY 26.11
RKDVA 27.09 N62
doi:10.1371/journal.pone.0001348.t002
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PLoS ONE | www.plosone.org 4 December 2007 | Issue 12 | e1348contrast to this observation, the alanine substitution of Lys at
position 2 reduced the binding affinity to the minimum extent; the
substitution failed to stretch into the same binding site containing
Glu11 and Asn62 instead of projecting out the binding groove
(Fig. 6C). In particular, the interactions of Arg and Lys with the
binding sites ensured the occurrence of binding and the direction
of the N-terminal of the peptide. Whereas, the alanine substitution
of Val at position 4 reduced the binding affinity to the maximum
extent and bound HLA-DR in a distinct manner from TP5,
projecting out the cleft (Fig. 6E). The substitution of Asp and Tyr
at positions 3 and 5 resulted in a moderate decrease of binding
affinity and variant binding sites without Glu11. Interestingly, both
the substitutions bound into the binding cleft (Fig. 6D, F).
Examination of the docking results revealed that TP5 was
predicted to be optimal for binding into the cleft within the
MHC molecules.
As mentioned above, the contacted residues Glu11 and Asn62
played a key role in mediating the binding affinity and orientation
(Table 2). In order to verify their effects on the binding between
TP5 and HLA-DR, the HLA-DR double mutant, replacing E11
and N62 with alanine (DR11/62), and two single mutants,
DRE11A (DR11), and DRN62A (DR62), were used as controls.
From Table 3, when TP5 bound to the mutant DR11, the binding
energy had a slight change; however, Ala11 completely lost its role
as a binding site. Whereas, when TP5 bound to the mutant DR62,
the binding energy had a distinct change; Ala62 remained to exert
a positive role as a binding site, suggesting that Asn anchor mainly
contributed to the binding energy. When the mutant DR11/62
was used, the binding energy increased markedly which was
basically equal to the sum of both the values above predicted,
demonstrating that Glu11 and Asn62 played their respective role
in the double mutant. These data suggested that the complex of
HLA-DR/TP5 was the most stable, and further indicated that the
molecular modeling was feasible for supporting the assumption of
TP5 binding to HLA-DR.
DISCUSSION
The role of TP5 in clinical treatment in immune system was well
established, however, the refined mechanism of its action is not
known in details. According to the main idea of immunomodu-
lation, we suppose that it were obligatory for TP5 to form complex
with MHC II before TP5 interacts with TCRs. For class II MHC
molecules, they bound peptides with various length [3]. More
importantly, a tentative DR motif that governs the fine-specificity
of antigen presentation had been well known recently [26]. For
TP5, it contains Val and Tyr residues which belong to basic
anchor motifs, providing multiple interaction sites. Especially, TP5
possesses a linear peptide whose structural flexibility may allow it
to associate with different receptors through conformational
changes. According to the rule of set of allowed anchor residues
(SAAR) [26], TP5 is theoretically expected to bind HLA-DR.
We report the first direct observation of MHC II/TP5 complex
formed in living APC in situ. On the basis of the double-reciprocal
plot of the dose-dependent fluorescence intensities (Fig. 3), the Kd
(7.2610
26 M) is close to the reported Kd value [27]. Furthermore,
with increasing the concentrations of TP5 in the range of 10
25 M
to 10
22 M, the fluorescence intensity decreased (Fig. 5A), reaching
36% inhibition at the concentration of 10
22 M as shown in
Fig. 5B. The inhibition was similar to the observation of human
EBV-transformed B cells inhibited by anti-HLA-DR antibody
reaching 44–52% [28]. The comparability in the level of inhibition
could be due to the higher levels of MHC II on the surface of
EBV-transformed B cells [29] and the occupied binding sites of
MHC II [2]. The main findings indicated that MHC II/TP5
complex was formed by the binding of TP5 to HLA-DR in living
cells. The affinity measured using living EBV-transformed B cells
are more applicable for functional recognition of MHC II/peptide
by T cells.
As far as MHC-binding motifs are concerned, anchors can be
divided into two different types: type 1 anchors that contribute to
the binding energy of the peptide, and type 2 anchors that
contribute to the peptide conformation [30]. Here, we performed
molecular modeling evaluations to analyze the interaction between
the anchors in the frame of TP5 and the binding sites within the
groove of HLA-DR. The alanine substitutions of TP5 were tested
for HLA-DR binding affinity. From the binding energies
presented in Table 2, it can be observed that the substitution at
positions 1 and 4 had a significant effect on the binding affinity;
the substitution at other positions resulted in only partial loss of
binding affinity. It implied that the substitution of TP5 at positions
1 and 4 formed instable complexes with HLA-DR. Further, the
anchor at positions 1 and 4 seemed to be obligatory as type 1
anchors due to decreasing the binding affinity by Ala substitution.
It was also noteworthy that the substitution at positions 2 and 4
neither bound to the same binding sites containing Glu11 and
Asn62 nor stretched into the binding groove (Fig. 6C, E). This
observation suggested that anchors at positions 2 and 4 mainly
exerted an effect on peptide conformation, and further implied
that the conformation of DR-bound peptide should be very
similar. With regard to positions 3 and 5, the substitution by Ala
resulted in a moderate binding affinity decrease and variant
binding sites containing Asn62 without Glu11, suggesting that
peptides with several anchors in frame were more likely to bind to
a particular binding site than those lacking partial anchors in
frame. The variation of binding affinity showed that anchors at
positions 1, 3 and 5 in the frame of TP5 actually interacted with
the receptor HLA-DR; however, anchor at position 2 primarily
involved in steric constraints. As for the Val at position 4, although
the amino acid served as type 2 anchors identified in previous
study [31], the contribution as type 1 anchors is more in the
present study. This observation exhibits an obligatory role for Val
anchor which is essential for HLA-DR/peptide interaction. The
functional analysis of TP5 is basically consistent with previous
study on the role of each amino acid in frame [31] other than
supplementing an important discovery to the effect of Val on TP5
binding receptor as type 1 anchors.
The alanine-substituted peptide variants bound less well to
HLA-DR than TP5 did, suggesting that Ala in the substitutions
exerted its effect indirectly by inducing a conformational change.
Especially, substitution of the N- and C-terminal residues with Ala
had revealed some unpredictably conformational changes both in
central peptide residues and in the MHC other than affecting the
stability of the complexes [32,33]. Thus, the substitution of
anchors can alter overall peptide conformation. Simultaneously, as
shown in Fig. 6, the binding space of TP5 and its alanine
Table 3. The effect of the mutants of HLA-DR on the
recognition of TP5.
......................................................................
Mutants Binding energy (kcal/mol) Key residues
DR 28.99 E11, N62
DR11 28.42 N62
DR62 27.78 E11, A62
DR11/62 27.46 A62
doi:10.1371/journal.pone.0001348.t003
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peptides. Thus, the binding groove likely permits flexibility in
peptides binding, which had been demonstrated before [34,35].
The results provide significant evidences that peptide variants by a
single Ala-substituted assume distinct conformations when they
bound to HLA-DR. In other words, the results show that there is
flexibility in peptide binding within the MHC II binding cleft.
In an attempt to gain insight into the interaction pattern, we
studied the influence of site-directed mutants of HLA-DR on the
peptide binding. The results demonstrated that Glu11 exerted its
role of binding site through forming H-bond by the interaction of
its side chain with the Lys anchor in the frame of TP5 (Fig. 7A, C).
Conversely, Ala11 completely lost the ability to interact with TP5
due to the lack of negative residue in its side chain (Fig. 7B, D),
which showed that Glu11 acted as a key effect on the binding
between TP5 and HLA-DR. DR62 resulted in significantly lower
binding affinity to level comparable to the binding by original DR
(Table 3). It can be seen that Asn62 interacted with the Arg and
Asp anchors in the frame of TP5 by its side chain (Fig. 7A, B).
However, Ala62 completely lost the interaction with TP5 by its
Figure 7. The 2D schemes of the predicted binding of TP5 to HLA-DR and its mutants. The schemes of TP5 binding HLA-DR (A), DR11 (B), DR62 (C),
and DR11/62 (D) were resulted from the Ligplot program [42].
doi:10.1371/journal.pone.0001348.g007
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of Ala62 (Fig. 7C, D), suggesting that the interaction by the main
chain weakened the binding affinity. The results examining the
recognition of the mutations of HLA-DR provided a sufficient
basis for the prediction of Glu11 and Asn62 within the groove
exerting respective effect on the binding pattern.
The collectively experimental and computational studies
supported the hypothesis that TP5 bound to HLA-DR with stable
conformation, and clarified the distribution of residue-residue
between the peptide and the receptor. This report focused on the
exploration of the binding affinity of TP5 to MHC II, which was
essential to understand the mechanism of TP5 triggering immune
response in vivo. More significantly, identification of the interaction
between TP5 and HLA-DR will advance our ability to develop
polypeptides for the study of MHC class II-restricted CD4+ T
lymphocyte responses.
MATERIALS AND METHODS
Peptide synthesis and conjugation with FITC
TP5 was synthesized and purified as described previously [36].
Conjugation of TP5 with Fluorescein isothiocyanate (FITC)
(Sigma, St.Louis, USA) was performed and purified as described
previously [37]. The identity of FITC-labeled TP5 was conducted
by laser-induced fluorescence spectral analysis (PTI, London
Ontario, Canada).
Cell culture
EBV-transformed B cells expressing HLA-DR molecules were
maintained in RPMI 1640 containing 2 mM L-glutamine
(HyClone Laboratories, UT, USA) supplemented with 10%
standard FBS (HyClone Laboratories, UT, USA) at 37uC and in
5% CO2. Expression of HLA-DR was verified using mAb-DR
L243 labeled with FITC (Pharmingen, San Diego, USA), by
incubation for 45 min on ice followed by CLSM and FCM.
Cellular peptide loading assay
We harvested 3610
5 cells, washed twice with phosphate-buffered
saline (PBS) buffer (pH 7.4) supplemented with 0.1% BSA and
0.05% NaN3. Ten mM FITC- labeled TP5 was added to the
treated cells in PBS (pH 7.4) containing 1% BSA (binding buffer),
then incubated for 2 h at 37uC. Thereafter, the cells were washed
twice and resuspended in 500 ml PBS, followed by CLSM analysis
using Leica Microsystems (TCS SP2, Heidelberg, Germany).
Direct binding of FITC-labeled TP5 to EBV-
transformed B cells
EBV-transformed B cells (3610
5 per sample) were incubated with
various concentrations of FITC-labeled TP5 in binding buffer for
2 h at 37uC. Thereafter, the cells were washed twice and
resuspended in 500 ml PBS, followed by flow cytometric analysis
using a FACSCan analyzer (Becton Dickinson Immunochemical
Systems, Mountain View, USA). A total of ten thousand events
were acquired for each sample. The MFI was used to evaluate the
binding ability of FITC-labeled TP5 to APC.
Competitive binding assay
EBV-transformed B cells (3610
5 per sample) were preincubated in
the presence of varying concentrations of TP5 in binding buffer for
2 h at 37uC. Then, the cells were washed and resuspended in
50 ml binding buffer, followed by incubation with 20 ml mAb-DR
L243 labeled with FITC for each sample for 45 min on ice in
dark. Thereafter, cells were washed twice and analyzed by FCM.
In each analysis, ten thousand cells were examined. Percent
inhibition was calculated as [(1–MFI in the presence of TP5/MFI
in the absence of TP5)6100%].
Molecular modeling
Both the numbers of energy evaluations and generations are very
important factors for the time that will be consumed and the
accurateness of the results that will be got. The docking
calculations will be stopped if anyone of the parameters is reached
whichever first comes. In this case, to determine the effect of the
number of energy evaluations, six groups of trials were performed
with 100 runs (Table 1). Six trials with different energy evaluation
parameters were chosen for the purpose of exploring which choice
could lead to the final binding mode. The maximum number of
generations was set to default (27000) so that the docking
calculation will be stopped based on the number of energy
evaluations. The maximum number of energy evaluations was set
to 100 million; the other parameters were defaults. We applied the
populations of 300 individuals to 100 independent runs. In
addition, the random docking method was applied to predict the
complexes between the receptors and the ligands in the Autodock.
Further, the two-step protocol was applied to confirm the
complex formation and to examine the interaction between TP5
and HLA-DR. In the present modeling system, HA peptide/HLA-
DR complex (PDB code 1J8H) was used as the reference. The
structure of TP5 was achieved based on the crystal nonapeptide by
mutating method [38]. The ligand TP5 was prepared using
AutoDockTools. Here, Amber-based ‘‘Kollman’’ partial atomic
charges and solvation parameters were applied to the atoms of the
receptor (HLA-DR) using the AutoDockTools software package.
Kollman charges were assigned to the atoms of the ligand.
In the first phase, TP5 was docked into the binding site by
means of the package Autodock 3.0.5 [39]. A three-dimensional
grid was created with 0.375 A ˚ spacing with a 126 A ˚6126 A ˚676 A ˚
grid box by the AutoGrid program for the binding site of the
receptor, which was used to evaluate the binding energy between
the inhibitor and the protein. Lennard-Jones parameters 12–10
and 12–6 were approximately used to simulate H-bonds and Van
der Waals interactions, respectively. The distance- dependent
dielectric permittivity of Mehler and Solmajer was used for the
calculation of the electrostatic grid maps [40]. The Lamarckian
genetic algorithm, the pseudo-Solis, and Wets methods were
applied for minimization by using defaults [39]. Solis and Wets
local searches were applied with a probability of 6%. A crossover
rate of 80% was used to generate new docking solutions for
subsequent generations, and one solution from each generation
was propagated to the next generation. Random starting positions
on the entire protein surface, random orientations, and torsions,
were used for the ligand. Evaluation of the results was performed
by sorting the binding energy predicted by docking conformations.
A cluster of analysis based on the root mean square deviation
(rmsd) value, referring to the starting position of the ligand, was
performed subsequently.
In the second phase, the lowest-energy complex predicted by
molecular docking was subjected to 1000 steps of energy
minimization by using the perl script of minAmber MMTSB_tool
for removing clashes and refining complex docked by using an
Amber-based procedure [38]. Namely, we performed a vacuum
minimization of the given structure over 700 steps of final
conjugate gradient minimization with 300 steps of initial steepest
descent minimization. As a somewhat realistic but very fast
method for representing aqueous solvent, we used a distance
dependent dielectric function with an epsilon value of 4. The non-
bonded cutoff radius was set to 16 A ˚. With respect to the above
Thymopentin Binding to HLA-DR
PLoS ONE | www.plosone.org 7 December 2007 | Issue 12 | e1348minimized complex, the evaluation of the predicted binding
energy was made by using the package Dcomplex [41], which is
the program for predicting the binding affinities of protein-protein
and protein-peptide complexes based on the Distance-scaled Finite
Ideal-gas Reference (DFIRE) energy function. The determination
of the interactions between ligands and receptors was illustrated by
using the package Pymol based on the minimized structures [42].
Next, we studied the dockings for alanine substitutions of TP5
through scanning the alanine on each position for the same
receptor (HLA-DR). Moreover, the HLA-DR double mutant
DR11/62 and two single mutants DR11, and DR62, were used by
molecular modeling method for the same ligand TP5. All
preparations and parameters were consistent with the contents
above described.
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